PD-1/PD-L1 Inhibitors Market Report 2017: Sales of the PD-1/PD-L1 Therapy Class have Grown from $84m in 2014 to $6,292m in 2016

Dublin, Jan. 11, 2018 -- The "PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology" report has been added to Research and Markets' offering.

Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic melanoma in July 2014, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have grown to become the leading class of immunotherapies in oncology worldwide.

Sales of the PD-1/PD-L1 therapy class have grown from $84m in 2014 to $6,292m in 2016, with five PD-1/PD-L1 inhibitors currently approved across a variety of tumor indications. Despite the success of these products, developers continue to face clinical and commercial challenges. Nonetheless, the broad applicability and strong initial success of PD-1/PD-L1 inhibitors in oncology means that companies are actively seeking ways to differentiate their products and increase their market share.

Key Topics Covered:

1 Overview of the current immuno-oncology market

• Ongoing developments in the PD-1/PD-L1 therapy space

2 Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical)

• Keytruda (pembrolizumab; Merck & Co)
• Tecentriq (atezolizumab; Roche/Chugai)
• Imfinzi (durvalumab; AstraZeneca)
• Bavencio (avelumab; Merck KGaA/Pfizer)

3 Challenges with PD-1/PD-L1 inhibitor development and treatment

4 An examination of:

• Non-small cell lung cancer (NSCLC)
• Bladder cancer

5 Looking forward: the future of immuno-oncology

For more information about this report visit https://www.researchandmarkets.com/research/c7kqcg/pd1pdl1?w=12

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Oncology Drugs , Oncology